JP2020517599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517599A5 JP2020517599A5 JP2019555959A JP2019555959A JP2020517599A5 JP 2020517599 A5 JP2020517599 A5 JP 2020517599A5 JP 2019555959 A JP2019555959 A JP 2019555959A JP 2019555959 A JP2019555959 A JP 2019555959A JP 2020517599 A5 JP2020517599 A5 JP 2020517599A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- formula
- unit
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims description 357
- 239000003814 drug Substances 0.000 claims description 357
- 150000003839 salts Chemical class 0.000 claims description 319
- 229910052739 hydrogen Inorganic materials 0.000 claims description 258
- 150000001875 compounds Chemical class 0.000 claims description 250
- 239000001257 hydrogen Substances 0.000 claims description 214
- 239000003446 ligand Substances 0.000 claims description 191
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 150
- 125000000217 alkyl group Chemical group 0.000 claims description 140
- 229910052799 carbon Inorganic materials 0.000 claims description 138
- 229910052757 nitrogen Inorganic materials 0.000 claims description 115
- 239000000203 mixture Substances 0.000 claims description 106
- -1 substituted - alcohol residue Chemical group 0.000 claims description 104
- 125000003118 aryl group Chemical group 0.000 claims description 96
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 93
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims description 80
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims description 80
- 125000001072 heteroaryl group Chemical group 0.000 claims description 66
- 125000005647 linker group Chemical group 0.000 claims description 62
- 150000001721 carbon Chemical group 0.000 claims description 60
- 150000008134 glucuronides Chemical group 0.000 claims description 59
- 229910052717 sulfur Inorganic materials 0.000 claims description 54
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 43
- 238000003776 cleavage reaction Methods 0.000 claims description 43
- 150000002431 hydrogen Chemical class 0.000 claims description 43
- 230000007017 scission Effects 0.000 claims description 43
- 125000004429 atom Chemical group 0.000 claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 39
- 125000005842 heteroatom Chemical group 0.000 claims description 38
- 125000004434 sulfur atom Chemical group 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 32
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 32
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 229910052760 oxygen Inorganic materials 0.000 claims description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 claims description 28
- 102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 claims description 28
- 108091005804 Peptidases Proteins 0.000 claims description 25
- 239000004365 Protease Substances 0.000 claims description 25
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 25
- 238000007363 ring formation reaction Methods 0.000 claims description 25
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 24
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 125000006850 spacer group Chemical group 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 21
- 125000005549 heteroarylene group Chemical group 0.000 claims description 21
- 108010016626 Dipeptides Proteins 0.000 claims description 20
- 125000002015 acyclic group Chemical group 0.000 claims description 20
- 125000002947 alkylene group Chemical group 0.000 claims description 20
- 125000004122 cyclic group Chemical group 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000000524 functional group Chemical group 0.000 claims description 17
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 16
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 14
- 239000005667 attractant Substances 0.000 claims description 13
- 125000000837 carbohydrate group Chemical group 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 12
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 150000001408 amides Chemical group 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000000732 arylene group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229960003966 nicotinamide Drugs 0.000 claims description 8
- 235000005152 nicotinamide Nutrition 0.000 claims description 8
- 239000011570 nicotinamide Substances 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- 125000005841 biaryl group Chemical group 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 125000006242 amine protecting group Chemical group 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 150000003512 tertiary amines Chemical group 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 238000005956 quaternization reaction Methods 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- KXSKAZFMTGADIV-UHFFFAOYSA-N 2-[3-(2-hydroxyethoxy)propoxy]ethanol Chemical compound OCCOCCCOCCO KXSKAZFMTGADIV-UHFFFAOYSA-N 0.000 claims description 4
- 101000693243 Homo sapiens Paternally-expressed gene 3 protein Proteins 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 4
- 102100025757 Paternally-expressed gene 3 protein Human genes 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 235000013477 citrulline Nutrition 0.000 claims description 4
- 229960002173 citrulline Drugs 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 4
- 230000003463 hyperproliferative effect Effects 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000012038 nucleophile Substances 0.000 claims description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 230000031902 chemoattractant activity Effects 0.000 claims 9
- 125000004404 heteroalkyl group Chemical group 0.000 claims 9
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 8
- 235000008206 alpha-amino acids Nutrition 0.000 claims 8
- 150000001576 beta-amino acids Chemical class 0.000 claims 8
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 4
- 125000003003 spiro group Chemical group 0.000 claims 4
- 150000001720 carbohydrates Chemical group 0.000 claims 3
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000001548 androgenic effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000000562 conjugate Substances 0.000 description 124
- 0 *NC(C=C[C@]1C=NC=CC1)=O Chemical compound *NC(C=C[C@]1C=NC=CC1)=O 0.000 description 33
- 239000000611 antibody drug conjugate Substances 0.000 description 14
- 229940049595 antibody-drug conjugate Drugs 0.000 description 14
- 238000010276 construction Methods 0.000 description 12
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 239000001301 oxygen Chemical class 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001414 amino alcohols Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000002829 nitrogen Chemical class 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- XGDNGYCXEPMDMT-UHFFFAOYSA-N CC(CC(C)(C)NC(NC(C)(C)I)=O)C(C)=O Chemical compound CC(CC(C)(C)NC(NC(C)(C)I)=O)C(C)=O XGDNGYCXEPMDMT-UHFFFAOYSA-N 0.000 description 1
- GERARCVVNNZXEK-KPIFQKDSSA-N CC(CC[C@H](C1C)N)C1=C Chemical compound CC(CC[C@H](C1C)N)C1=C GERARCVVNNZXEK-KPIFQKDSSA-N 0.000 description 1
- NWIPVDBSQYRMNL-UHFFFAOYSA-N CC1C=C=CC1 Chemical compound CC1C=C=CC1 NWIPVDBSQYRMNL-UHFFFAOYSA-N 0.000 description 1
- KAACOBLRFGFVJY-UHFFFAOYSA-N CCCCCCCC(N(C1CCCCC1)OCCN(C)C(c1ccccc1)=O)=O Chemical compound CCCCCCCC(N(C1CCCCC1)OCCN(C)C(c1ccccc1)=O)=O KAACOBLRFGFVJY-UHFFFAOYSA-N 0.000 description 1
- DQMAEKOMFBRRSO-UHFFFAOYSA-N CCCCCCCCC(N(CC1)CCC1O)=O Chemical compound CCCCCCCCC(N(CC1)CCC1O)=O DQMAEKOMFBRRSO-UHFFFAOYSA-N 0.000 description 1
- GOVXKUCVZUROAN-UHFFFAOYSA-N CCc1c[nH]c2ccccc12 Chemical compound CCc1c[nH]c2ccccc12 GOVXKUCVZUROAN-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023113358A JP2023119064A (ja) | 2017-04-27 | 2023-07-10 | 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490733P | 2017-04-27 | 2017-04-27 | |
| US62/490,733 | 2017-04-27 | ||
| US201762573987P | 2017-10-18 | 2017-10-18 | |
| US62/573,987 | 2017-10-18 | ||
| PCT/US2018/030018 WO2018201087A1 (en) | 2017-04-27 | 2018-04-27 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023113358A Division JP2023119064A (ja) | 2017-04-27 | 2023-07-10 | 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517599A JP2020517599A (ja) | 2020-06-18 |
| JP2020517599A5 true JP2020517599A5 (enExample) | 2021-06-17 |
| JP7425606B2 JP7425606B2 (ja) | 2024-01-31 |
Family
ID=62165714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555959A Active JP7425606B2 (ja) | 2017-04-27 | 2018-04-27 | 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート |
| JP2023113358A Pending JP2023119064A (ja) | 2017-04-27 | 2023-07-10 | 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023113358A Pending JP2023119064A (ja) | 2017-04-27 | 2023-07-10 | 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11931414B2 (enExample) |
| EP (1) | EP3615081A1 (enExample) |
| JP (2) | JP7425606B2 (enExample) |
| KR (1) | KR20190141181A (enExample) |
| CN (1) | CN110799217A (enExample) |
| AU (2) | AU2018258687C1 (enExample) |
| BR (1) | BR112019022445A2 (enExample) |
| CA (1) | CA3060206A1 (enExample) |
| IL (1) | IL269794A (enExample) |
| MA (1) | MA51189A (enExample) |
| MX (2) | MX2019012194A (enExample) |
| SG (1) | SG11201909563VA (enExample) |
| TW (1) | TW201904613A (enExample) |
| WO (1) | WO2018201087A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI851531B (zh) | 2016-08-09 | 2024-08-11 | 美商思進公司 | 具有改善之生理化學性質之具自我穩定連接子之藥物結合物 |
| CA3039589A1 (en) | 2016-10-18 | 2018-04-26 | Seattle Genetics, Inc. | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
| CA3060206A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| CN110339181A (zh) * | 2019-07-02 | 2019-10-18 | 中国药科大学 | 一种基于点击反应的pH响应型纳米制剂及其制法和应用 |
| CN111454327B (zh) * | 2020-04-02 | 2024-07-26 | 中国人民解放军第二军医大学 | 一种nampt蛋白降解靶向嵌合体及其制备方法和应用 |
| AU2021251875A1 (en) * | 2020-04-10 | 2022-11-03 | Seagen Inc. | Charge variant linkers |
| WO2024052685A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy |
| CN116092586B (zh) * | 2023-03-10 | 2025-11-04 | 西北工业大学 | 一种基于生物电子等排体搜索平台的数据处理方法 |
| WO2025162305A1 (zh) * | 2024-02-01 | 2025-08-07 | 浙江养生堂天然药物研究所有限公司 | 含季铵盐的抗体偶联药物及其医药用途 |
| CN119219604B (zh) * | 2024-09-25 | 2025-11-18 | 大连理工大学 | 一种吡啶季铵盐类fk866前药、其制备方法及应用 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
| GB9711125D0 (en) | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| WO2000061559A1 (en) | 1999-04-09 | 2000-10-19 | Shionogi Bioresearch Corp. | N-substituted cyanoguanidine compounds |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| BR0309988A (pt) | 2002-05-17 | 2005-02-22 | Leo Pharma As | Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| EP2354163A3 (en) | 2005-09-26 | 2013-04-24 | Medarex, Inc. | Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies |
| US8257706B2 (en) | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| WO2009086835A1 (en) | 2008-01-11 | 2009-07-16 | Topotarget A/S | Novel cyanoguanidines |
| EP2240495B1 (en) | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| NZ610239A (en) | 2008-04-30 | 2014-11-28 | Immunogen Inc | Cross-linkers and their uses |
| WO2009140418A2 (en) | 2008-05-14 | 2009-11-19 | Five Prime Therapeutics, Inc. | Compositions and methods for treating arthritis and/or diseases involving cartilage degeneration |
| WO2009156421A1 (en) | 2008-06-24 | 2009-12-30 | Topotarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide |
| RU2011111728A (ru) | 2008-08-29 | 2012-10-10 | Топотаргет А/С (Dk) | Новые производные мочевины и тиомочевины |
| CA2764694A1 (en) | 2009-06-09 | 2010-12-16 | Topotarget A/S | Pyridinyl derivatives asinhibitors of enzyme nicotinamide phosphoribosyltransferase |
| CA2768338A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| CN103270023B (zh) | 2010-09-03 | 2016-11-02 | 福马Tm有限责任公司 | 作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物 |
| EP2611804A1 (en) | 2010-09-03 | 2013-07-10 | Forma TM, LLC. | Novel compounds and compositions for the inhibition of nampt |
| AU2011329233A1 (en) | 2010-11-15 | 2013-05-23 | Abbvie Deutschland Gmbh & Co Kg | NAMPT and ROCK inhibitors |
| MX2013005479A (es) | 2010-11-15 | 2013-06-12 | Abbvie Inc | Inhibidores de nampt. |
| EP2648752B1 (en) | 2010-12-06 | 2017-02-15 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| RU2616612C2 (ru) | 2011-05-04 | 2017-04-18 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| MX347459B (es) | 2011-05-09 | 2017-04-26 | Forma Tm Llc | Nuevos compuestos y composiciones para la inhibición de nampt. |
| EP2739144A4 (en) | 2011-06-20 | 2015-04-01 | Alzheimer S Inst Of America Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| CA2855510A1 (en) | 2011-11-11 | 2013-05-16 | Abbvie Inc. | Nampt inhibitors |
| WO2013082150A1 (en) | 2011-11-30 | 2013-06-06 | The Curators Of The University Of Missouri | Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt) |
| SG11201404354UA (en) | 2012-02-17 | 2014-10-30 | Seattle Genetics Inc | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
| WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
| WO2013130935A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Amido-benzyl sulfoxide derivatives |
| WO2013127268A1 (en) | 2012-03-02 | 2013-09-06 | Genentech,Inc. | Amido-benzyl sulfone and sulfonamide derivatives |
| CN104684906B (zh) | 2012-05-11 | 2017-06-09 | 艾伯维公司 | Nampt抑制剂 |
| MX2014013758A (es) | 2012-05-11 | 2015-02-05 | Abbvie Inc | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. |
| PE20150224A1 (es) | 2012-05-11 | 2015-03-08 | Abbvie Inc | Inhibidores del nampt |
| WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
| AR091023A1 (es) | 2012-05-11 | 2014-12-30 | Abbvie Inc | Inhibidores del nampt |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CN105121421B (zh) | 2012-11-05 | 2020-10-02 | 辉瑞公司 | 司普力西欧他汀类似物 |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| WO2014111871A1 (en) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
| ITTO20130356A1 (it) | 2013-05-03 | 2014-11-04 | Uni Degli Studi Del Piemonte Orientale Ame | Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi |
| EP3055304A1 (en) | 2013-10-09 | 2016-08-17 | Eli Lilly and Company | Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors |
| NZ758049A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| KR102442906B1 (ko) | 2013-12-19 | 2022-09-14 | 씨젠 인크. | 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커 |
| CN106458934B (zh) | 2014-04-18 | 2019-08-16 | 米伦纽姆医药公司 | 喹喔啉化合物及其用途 |
| TW201625641A (zh) | 2014-05-22 | 2016-07-16 | 健臻公司 | Ｎａｍｐｔ抑制劑及方法 |
| CA2954328A1 (en) | 2014-07-23 | 2016-01-28 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
| FI3900742T3 (fi) | 2014-09-11 | 2024-08-16 | Seagen Inc | Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen |
| CN104557863B (zh) | 2014-12-18 | 2017-03-15 | 中国科学院广州生物医药与健康研究院 | 一种新型烟酰胺磷酸核糖转移酶抑制剂及其合成方法与应用 |
| CA2974078A1 (en) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
| CA3039589A1 (en) | 2016-10-18 | 2018-04-26 | Seattle Genetics, Inc. | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
| CA3060206A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
-
2018
- 2018-04-27 CA CA3060206A patent/CA3060206A1/en active Pending
- 2018-04-27 TW TW107114520A patent/TW201904613A/zh unknown
- 2018-04-27 WO PCT/US2018/030018 patent/WO2018201087A1/en not_active Ceased
- 2018-04-27 AU AU2018258687A patent/AU2018258687C1/en not_active Ceased
- 2018-04-27 CN CN201880042426.XA patent/CN110799217A/zh active Pending
- 2018-04-27 KR KR1020197033551A patent/KR20190141181A/ko not_active Ceased
- 2018-04-27 MX MX2019012194A patent/MX2019012194A/es unknown
- 2018-04-27 JP JP2019555959A patent/JP7425606B2/ja active Active
- 2018-04-27 US US16/608,748 patent/US11931414B2/en active Active
- 2018-04-27 MA MA051189A patent/MA51189A/fr unknown
- 2018-04-27 EP EP18724738.2A patent/EP3615081A1/en not_active Withdrawn
- 2018-04-27 BR BR112019022445-9A patent/BR112019022445A2/pt active Search and Examination
- 2018-04-27 SG SG11201909563V patent/SG11201909563VA/en unknown
-
2019
- 2019-10-03 IL IL26979419A patent/IL269794A/en unknown
- 2019-10-10 MX MX2023014831A patent/MX2023014831A/es unknown
-
2022
- 2022-10-05 AU AU2022246407A patent/AU2022246407B2/en not_active Withdrawn - After Issue
-
2023
- 2023-07-10 JP JP2023113358A patent/JP2023119064A/ja active Pending
-
2024
- 2024-01-16 US US18/414,104 patent/US20240293554A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517599A5 (enExample) | ||
| JP2019524759A5 (enExample) | ||
| JP2023082171A5 (enExample) | ||
| ES2257756T3 (es) | Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias. | |
| US7442682B2 (en) | Transepithelial delivery of peptides with incretin hormone activities | |
| JP2019501131A5 (enExample) | ||
| TW200813028A (en) | Improved prodrugs of CC-1065 analogs | |
| JP2023119064A (ja) | 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート | |
| JP6704900B2 (ja) | ポリオキサゾリン抗体薬物複合体 | |
| Baraldi et al. | Hybrid molecules between distamycin A and active moieties of antitumor agents | |
| CN107198778A (zh) | 用经不可切割接头连接的细胞结合剂美登木素生物碱偶联物 | |
| CN105377304B (zh) | 鹅膏毒肽衍生物 | |
| TW201818970A (zh) | 菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞 | |
| JP6721512B2 (ja) | がん及び炎症性疾患の治療のための結合体及びプロドラッグ | |
| CN107105660A (zh) | 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法 | |
| JPWO2008056654A1 (ja) | 核酸系代謝拮抗剤の高分子誘導体 | |
| CA3117666A1 (en) | Biomarkers of metap2 inhibitors and applications thereof | |
| JP2019511497A5 (enExample) | ||
| JP2024534502A5 (enExample) | ||
| AU2006218187A1 (en) | Transport of nano- and macromolecular structures into cytoplasm and nucleus of cells | |
| JP2026509773A (ja) | アルブミン結合性部分を含む薬物化合物 | |
| EP3484523A1 (en) | Conjugation method for carrier-linked prodrugs | |
| JP2019520342A5 (enExample) | ||
| US8791075B2 (en) | Methods and compositions for inhibition of BCL6 repression | |
| KR20190004812A (ko) | 폴리머 링커 및 이의 용도 |